Skip to main content

Clinical Trials › NCT06372145

Active, Not RecruitingPhase 3

A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.

Sponsored by Sanofi

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
2500
Target enrollment
27
U.S. states
Apr 2024
Start date
Apr 2029
Expected completion

Interventions / Treatments

TolebrutinibPlaceboTeriflunomide

Conditions studied

Relapsing Multiple SclerosisSecondary Progressive Multiple SclerosisProgressive Relapsing Multiple Sclerosis

Where this trial is running (52 sites)

Florida7 sites
Boca Raton · Gainesville · Maitland · +4 more
Ohio5 sites
Centerville · Cleveland · Columbus · +2 more
California4 sites
Los Alamitos · Los Angeles · San Diego · +1 more
Michigan3 sites
Detroit · Farmington Hills · Owosso
New York3 sites
New York · Patchogue · Stony Brook
Alabama2 sites
Birmingham · Cullman
Colorado2 sites
Denver · Fort Collins
Illinois2 sites
Northbrook · Springfield
Kentucky2 sites
Lexington · Louisville
Louisiana2 sites
Baton Rouge · New Orleans
Boston · Worcester
Minnesota2 sites
Golden Valley · Rochester
Missouri2 sites
Ozark · St Louis
Arizona1 site
Phoenix
Washington D.C.
Georgia1 site
Savannah
Indiana1 site
Fort Wayne
Kansas1 site
Kansas City
Nevada1 site
Las Vegas
Albuquerque
Winston-Salem
Oregon1 site
Portland
Greenville
Tennessee1 site
Knoxville
Texas1 site
San Antonio
Vermont1 site
Burlington
Virginia1 site
Richmond

Participating MS centers on MS Buddy (32)

Premier Neurology, PC
Greenville, SC

MS centers in Florida

Compare treatment centers near a trial site by center type, providers and trials.

View Florida centers

More Phase 3 trials

Browse all Phase 3 MS trials
The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play